Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up

References

• Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789–96
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994;151:1744–52
   PubMed Web of Science ®Google Scholar
• Dossenbach MRK, Beuzen JN, Avnon M, Belmaker RH, Elizur A, Mark M, et al. The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. Clin Ther 2000;22:1021–34
   PubMed Web of Science ®Google Scholar
• Ohaeri JU. Naturalistic study of olanzapine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder. East Afr Med J 2000;77:86–92
   PubMed Web of Science ®Google Scholar
• Dursun SM, Gardner DM, Bird DC, Flinn J. Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. Can J Psychiatry 1999;44:701–4
   PubMed Web of Science ®Google Scholar
• Conley RR, Kelly DL, Gale EA. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr Res 1998;33:95–101
   Google Scholar
• Martin J, Gomez JC, Garcia-Bernardo E, Cuesta M, Alvarez E, Gurpegui M, et al. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. J Clin Psychiatry 1997;58:479–83
   Google Scholar
• Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry 1999;45:403–11
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Volavka J, Lieberman J, Sheitman B, Citrome L, Chakos M, et al. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. J Clin Psychopharmacol 2001;21:448–53
   PubMed Web of Science ®Google Scholar
• Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998;155:914–20
   PubMed Web of Science ®Google Scholar
• Sanders RD, Mossman D. An open trial of olanzapine in patients with treatment-refractory psychoses. J Clin Psychopharmacol 1999;19:62–6
   PubMed Web of Science ®Google Scholar
• Taylor DM, Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics. J Psychopharmacol 2000;14:409–18
   PubMed Web of Science ®Google Scholar
• Conlon L, Fahy TJ, O’Toole R, Gilligan J, Prescott C. Risperidone in chronic schizophrenia: a detailed audit, open switch study and two-year follow-up of patients on depot medication. Eur Psychiatry 2002:17:459–65
   PubMed Web of Science ®Google Scholar
• Margolese HC, Chouinard G, Beauclair L, Belanger M-C. Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 2002;22:347–52
   PubMed Web of Science ®Google Scholar
• Lindstrom E, Eriksson B, Hellgren A, von Knorring L, Eberhard G. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995;17:402–12
   PubMed Web of Science ®Google Scholar
• Drew LR, Griffiths KM, Hodgson DM. A five year follow-up study of the use of clozapine in community practice. Aust N Z Psychiatry 2002;36:780–6
   Google Scholar
• Reid WH, Mason M. Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system. J Clin Psychiatry 1998;59:189–94
   Google Scholar
• Marinovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR. The side-effects of clozapine: a four year follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:537–44
   PubMed Web of Science ®Google Scholar
• Mattes JA. Clozapine for refractory schizophrenia: an open study of 14 patients treated up to 2 years. J Clin Psychiatry 1989;50:389–91
   PubMed Web of Science ®Google Scholar
• Schmauss M, Wolff R, Erfurth A, Ruther E. Tolerability of long term clozapine treatment. Psychopharmacology (Berl) 1989;99(Suppl):105–8
   Google Scholar
• Lindstrom LH. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 1988;77:524–529
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr, Hamilton SH, Dossenbach M. Relapse prevention with olanzapine. Schizophr Res 2000;41:196
   Web of Science ®Google Scholar
• Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111–23
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125–37
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457–65
   PubMed Web of Science ®Google Scholar
• Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley CM Jr. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 1998;172:499–505
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Publication ADM 76–338 ed. Bethesda, Md: US Department of Health, Education, and Welfare, 1976
   Google Scholar
• Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry 2001;62:757–71
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996;124:159–67
   PubMed Web of Science ®Google Scholar
• Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000;15:121–31
   PubMed Web of Science ®Google Scholar
• Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med 2000;30: 95–105
   PubMed Web of Science ®Google Scholar
• Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999;20:491–505
   PubMed Web of Science ®Google Scholar
• Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158:1149–51
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Roychowdhury SM, Milton DR, Hill AL. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J Clin Psychiatry 2001;62(Suppl 2):17–21
   PubMed Web of Science ®Google Scholar
• Karagianis JL, Dawe IC, Thakur A, Begin S, Raskin J, Roychowdhury SM. Rapid tranquilization with olanzapine in acute psychosis: a case series. J Clin Psychiatry 2001;62(Suppl2):12–16
   PubMedGoogle Scholar
• Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59:441–8
   PubMed Web of Science ®Google Scholar
• Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001;21:389–97
   PubMed Web of Science ®Google Scholar
• Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25–40
   PubMed Web of Science ®Google Scholar
• Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765–74
   PubMed Web of Science ®Google Scholar
• Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001;23:1839–54
   PubMed Web of Science ®Google Scholar
• Baker RW, Kinon BJ, Liu H, Richey A, Hill AL, Bergstrom RFP, et al. Effectiveness of rapid initial dose escalation of oral olanza-pine for acute agitation. Schizophr Res 2002;53(Suppl 1):193
   Google Scholar
• Karagianis JL, Phillips LC, Hogan KP, LeDrew KK. Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature. Ann Pharmacother 1999;33:623–30
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr, Tollefson GD, Tran PV. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 1997;58(Suppl 10):7–12
   Google Scholar
• Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16–22
   Google Scholar
• Bailey LG, Maxwell S, Brandabur MM. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients. Psychopharmacol Bull 1997;33: 177–81
   PubMed Web of Science ®Google Scholar
• Dixon L, Weiden PJ, Haas G, Sweeney J, Frances AJ. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Compr Psychiatry 1992;33:121–2
   PubMed Web of Science ®Google Scholar
• Olivera AA, Kiefer MW, Manley NK. Tardive dyskinesia in psychiatric patients with substance use disorders. Am J Drug Alcohol Abuse 1990;16:57–66
   PubMed Web of Science ®Google Scholar
• Zaretsky A, Rector NA, Seeman MV, Fornazzari X. Current cannabis use and tardive dyskinesia. Schizophr Res 1993;11:3–8
   PubMed Web of Science ®Google Scholar
• Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994;51:273–9
   PubMed Web of Science ®Google Scholar
• Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990;264:2511–18
   Google Scholar
• Buckley PF. Substance abuse in schizophrenia: a review. J Clin Psychiatry 1998;59(Suppl 3):26–30
   PubMed Web of Science ®Google Scholar
• Noordsy DL, O’Keefe C. Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting. J Clin Psychiatry 1999;60\(Suppl19):47–51; discussion 52–3
   PubMedGoogle Scholar
• Albanese MJ, Khantzian EJ, Murphy SL, Green AI. Decreased substance use in chronically psychotic patients treated with clozapine. Am J Psychiatry 1994;151:780–1
   PubMed Web of Science ®Google Scholar
• Buckley P, Thompson PA, Way L, Meltzer HY. Substance abuse and clozapine treatment. J Clin Psychiatry 1994;55(Suppl B):114–16
   PubMed Web of Science ®Google Scholar
• Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988;85:5274–8
   PubMed Web of Science ®Google Scholar
• Hutchison KE, Swift R, Rohsenow DJ, Monti PM, Davidson D, Almeida A. Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology (Berl) 2001;155:27–34
   PubMed Web of Science ®Google Scholar
• Bano MD, Mico JA, Agujetas M, Lopez ML, Guillen JL. Olanzapine efficacy in the treatment of cocaine abuse in methadone maintenance patients. Interaction with plasma levels. Actas Esp Psiquiatr 2001;29:215–20
   PubMed Web of Science ®Google Scholar
• Misra LK, Kofoed L, Oesterheld JR, Richards GA. Olanzapine treatment of methamphetamine psychosis. J Clin Psychopharmacol 2000;20:393–4
   PubMed Web of Science ®Google Scholar